---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028830"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:12:35.288977+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte CEO rebuts NYT article questioning FDA approval of Symvess

## Summary
- FDA took 19 extra weeks after PDUFA date, consulted three outside surgeons before approving Symvess on Dec 19, 2024.
- Dr. Lee, cited as source, resigned from FDA months before approval; his LinkedIn says he 'retired' after a decade.
- CEO disputes claim synthetic grafts never rupture; cites MAUDE database showing >25% failures from rupture/death.
- In Ukrainian wartime study, all Symvess-treated limbs retained at 30 days with zero infections.
- Post-approval study planned to confirm safety; prior studies on 600+ patients never halted for safety.

## SEC filing metadata
- accession: 0001104659-25-028830
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/0001104659-25-028830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/tm2510708d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028830
- JSON: https://secwatch.observer/filing/0001104659-25-028830.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.